Novel structure-based transglutaminase 2 inhibitors

30 Oct 2024, 15:50
15m
134/4-406 (MLIT)

134/4-406

MLIT

20
Oral Life Science Life Science

Speaker

Sergey Ivashchenko (Moscow Institute of Physics and Technology)

Description

Among all of the human transglutaminases (TGases), transglutaminase 2 (TG2) is the most present one, existing in all of the tissues and organs of the human body. The protein has several conformations and functions, including protein crosslinking, apoptosis, immune response and calcium signaling. Moreover, TG2 also has the least variability in its coding sequence among the family of proteins, being the most conservative TGase. All of these facts combined highlight the necessity of the protein in the normal development of human organism and show the importance of studying it.
We obtained the first completely resolved TG2 structure using AlphaFold2 and validated it with developed molecular docking and molecular dynamics protocols. We also assembled a library of compounds similar to the existing TG2 inhibitors and verified the efficiency of novel compounds using in silico techniques.
We acknowledge the support from the Ministry of Science and Higher Education of the RF, project FSMF-2023-0010; “Integrated structural biology and genetics for the production of protein preparations and biologically active substances as new food and non-food products.”

Primary author

Sergey Ivashchenko (Moscow Institute of Physics and Technology)

Co-authors

Dr Alexey Vlasov (Moscow Institute of Physics and Technology) Anastasia Alexandrova (Moscow Institute of Physics and Technology) Dr Dmitry Shulga (Department of Chemistry, Moscow State University) Egor Zinovev (Moscow Institute of Physics and Technology) Mikhail Akulinin (Moscow Institute of Physics and Technology) Vladimir Ivashchenko (Moscow Institute of Physics and Technology)

Presentation materials